Most experience exists for sitagliptin (Merck) and vildagliptin (Novartis), which both have a long duration of action, allowing once-daily administration. In drug-naïve subjects with type 2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback